Posted by Michael Wonder on 19 Jan 2018
Drug maker raises U.S. price of muscular dystrophy treatment
18 January 2018 - Cost of drug Emflaza, which came under scrutiny last year, will go up by 9% for regular dosage.
PTC Therapeutics this month increased the list price of its muscular-dystrophy treatment by about 9%, to more than $65,000 annually for a common dosage.
The price increase again puts a spotlight on Emflaza, a decades-old steroidal drug that many U.S. patients had been paying $1,200 or less annually to import from Europe before the FDA last year approved the drug for U.S. sale as a treatment for Duchenne muscular dystrophy. The rare genetic disease affects up to 12,000 Americans, most of whom are boys.
